

## II. LISTING OF THE CLAIMS

### Claims 1-2. (Cancelled)

3. (Currently amended) A drug packaging system comprising ~~packaging material~~ comprising therein combined prescription drug therapy comprising:

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; and

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof; and

packaging material comprising a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage form forms of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage form forms of naproxen or a pharmaceutically acceptable salt thereof.

### Claims 4-5. (Cancelled)

6. (Previously presented) The drug packaging system of claim 3, wherein each unit dosage form is independently selected from the group consisting of a tablet, capsule, gel cap, and a caplet.

### Claims 7-15. (Cancelled)

16. (Previously presented) The drug packaging system of claim 3 wherein said system comprises unit doses for up to 28 days.

BEST AVAILABLE COPY

17. (Previously presented) The drug packaging system of claim 3 wherein said system comprises unit doses for 7-14 days.

Claim 18. (Cancelled)

19. (Currently amended) A method of treating a disease or condition comprising:

(a) arranging

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; into

a blister package comprising:

(i) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage form forms of lansoprazole or pharmaceutically acceptable salt thereof, and

(ii) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage form forms of naproxen or a pharmaceutically acceptable salt thereof;

to form a drug packaging system;

(b) rupturing one or more substrates to dispense one or more unit doses from the drug packaging system; and

(c) administering said one or more dispensed dosage forms to a human patient according to indicia included in said packaging system, said indicia providing dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof; and.

20. (Original) The method of claim 19 which provides therapy for 1-28 days.

Claim 21. (Cancelled)

300.1033

22. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof are capsules.

23. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof are tablets.

24. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole comprise 15 mg lansoprazole.

25. (Previously presented) The drug packaging system of claim 3, wherein the unit dosage forms containing naproxen comprise 500 mg naproxen.

**Claim 26. (Cancelled)**

27. (Amended) The drug packaging system of claim 26 3, wherein the indicia is located on the unit dosage forms.

28. (Amended) The drug packaging system of claim 26 3, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

29. (Previously presented) The drug packaging system of claim 3, wherein one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof is suitable for once daily dosing.

30. (Previously presented) The drug packaging system of claim 3, further comprising indicia that provides information to aid with removal of the unit dosage forms.

31. (Previously presented) The drug packaging system of claim 30, wherein the indicia is located on the unit dosage forms.

32. (Previously presented) The drug packaging system of claim 30, wherein the indicia is located on the blister layers, rupturable substrates or on other packaging material.

33. (Currently amended) A drug packaging system comprising ~~packaging material comprising therein~~ combined prescription drug therapy comprising:

unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof; and

unit dosage forms containing an NSAID base or a pharmaceutically acceptable salt thereof; and

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and NSAID or pharmaceutically acceptable salt thereof; and

packaging material comprising a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one unit dosage form of said NSAID base or pharmaceutically acceptable salt thereof.

Please add the following new claims:

34. (New) The drug packaging system of claim 3, wherein the indicia is located on the packaging material.

35. (New) A drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of lansiprazole or a pharmaceutically acceptable salt thereof and one or more unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; and

300.1033

indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**